Ozempic is Novo Nordisk’s brand of semaglutide, approved for type 2 diabetes. It is a weekly injection, and FDA-approved — Tier A for that use.
It is the same molecule as Wegovy. The difference is the label: Ozempic is approved for diabetes, Wegovy for weight management, and their dose ranges differ. Weight loss on Ozempic is well known but is an off-label use of a diabetes drug — the weight-management evidence was gathered under the Wegovy label.
What’s reported as a downside. A 2024 FAERS analysis found semaglutide carried the strongest signal in its class for metabolic and nutritional adverse events, such as nausea and vomiting.[1] FAERS reports are voluntary and cannot prove cause.
For what it actually costs by route, see the cost calculator.